This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Santo Holding GMBH
Drug Names(s): FYB 203, FYB-203, Biosimilar Eylea, Biosimilar aflibercept
FYB203 is a biosimilar of Regeneron's approved drug, Eylea.
Eylea (the VEGF Trap-Eye) is a fully human, soluble VEGF receptor fusion protein that binds all forms of VEGF-A and related placental growth factor (PlGF). The VEGF Trap-Eye is designed to block the interaction of these growth factors with cell-surface receptors, thereby preventing the subsequent formation of the new blood vessels that play an important role in the development of eye diseases such as wet AMD.
Formycon and Santo
In May 2015, Formycon announced the signing of an exclusive, global out-licensing deal for its FYB203 biosimilar drug, with Santo Holding as licensing partner. The newly signed agreement will ensure that Formycon has project funding in place all the way through to market introduction.
Under the agreement, Santo Holding will assume responsibility for, and the costs of, all further development activities, production and marketing of the Formycon biosimilar drug. In return, Santo Holding will receive exclusive worldwide marketing rights for FYB203. Pharmaceutical product development through to regulatory approval will remain in the hands of Formycon, while clinical development will be carried out by Bioeq, which manages biosimilar product development activities on behalf of Santo Holding.
Under the terms of the new agreement, Formycon will receive an immediate payment in the amount of several millions, along with ongoing payment for its...See full deal structure in Biomedtracker
Partners: Formycon AG
Additional information available to subscribers only: